Form 4: Centessa GC Exercises Options, Sells Shares

Centessa Pharmaceuticals' General Counsel, Iqbal J Hussain, exercised stock options and subsequently sold 6,000 ordinary shares under a pre-arranged trading plan.

Summary

• Iqbal J Hussain, General Counsel of Centessa Pharmaceuticals plc, reported transactions on November 17, 2025.
• Hussain exercised options to acquire 6,000 Ordinary Shares at an exercise price of $5.84 per share.
• Concurrently, Hussain sold 6,000 Ordinary Shares at a weighted average price of $27.6392 per share, with prices ranging from $27.505 to $27.86.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2024.
• Following these transactions, Hussain beneficially owns 105,386 Ordinary Shares directly.
• Hussain also holds 221,559 derivative securities in the form of share options, with an exercise price of $5.84.
• The vesting schedule for the options involved 25% vesting on February 19, 2022, and the remaining 75% vesting in 36 monthly installments thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (option exercise and sale) under a 10b5-1 plan, which does not typically signal new fundamental information about the company's performance or outlook.

Positives

• The executive realized significant value from stock options, selling shares at $27.6392 after exercising at $5.84, indicating a substantial gain on the exercised portion.
• The transaction was executed under a Rule 10b5-1 trading plan, which demonstrates pre-planned financial management and reduces concerns about opportunistic insider trading.

Negatives

• An insider sale, even if pre-planned, could be interpreted by some investors as a signal that the executive does not anticipate significant further short-term upside in the stock price, although this is a routine part of executive compensation and financial planning.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even if planned, might be viewed with slight caution, but the pre-arranged nature mitigates negative interpretations. The transaction itself is a small percentage of the company's overall shares and is unlikely to have a material impact on the company's valuation or operations.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares. Such transactions, especially when executed under a Rule 10b5-1 plan, are typically for personal financial management and do not inherently signal a change in the company's fundamental prospects or an executive's long-term view. Therefore, this specific filing alone does not provide a basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it does not alter the existing investment thesis for Centessa Pharmaceuticals.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Transaction, Stock Options, Share Sale, Iqbal J Hussain, Rule 10b5-1